Greenfinch Gemma, Hamilton Calum A, Donaghy Paul C, Firbank Michael, Barnett Nicola A, Allan Louise, Petrides George S, Taylor John-Paul, O'Brien John T, Thomas Alan J
Newcastle University Translational and Clinical Research Institute, Newcastle, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; and University College London Hospital, London, UK.
Newcastle University Translational and Clinical Research Institute, Newcastle, UK.
BJPsych Open. 2024 Dec 5;10(6):e223. doi: 10.1192/bjo.2024.766.
The aim of this study was to determine whether there was a significant change in cardiac [123I]-metaiodobenzylguanidine uptake between baseline and follow-up in individuals with mild cognitive impairment with Lewy bodies (MCI-LB) who had normal baseline scans. Eight participants with a diagnosis of probable MCI-LB and a normal baseline scan consented to a follow-up scan between 2 and 4 years after baseline. All eight repeat scans remained normal; however, in three cases uptake decreased by more than 10%. The mean change in uptake between baseline and repeat was -5.2% (range: -23.8% to +7.0%). The interpolated mean annual change in uptake was -1.6%.
本研究的目的是确定基线扫描正常的路易体轻度认知障碍（MCI-LB）患者在基线和随访之间心脏[123I]-间碘苄胍摄取是否有显著变化。八名诊断为可能的MCI-LB且基线扫描正常的参与者同意在基线后2至4年进行随访扫描。所有八次重复扫描均保持正常；然而，在三例中摄取量下降超过10%。基线和重复扫描之间摄取量的平均变化为-5.2%（范围：-23.8%至+7.0%）。摄取量的内插平均年变化为-1.6%。
